World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03941444
Date of registration: 06/05/2019
Prospective Registration: Yes
Primary sponsor: Anavex Life Sciences Corp.
Public title: ANAVEX2-73 Study in Patients With Rett Syndrome AVATAR
Scientific title: A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome
Date of first enrolment: May 6, 2019
Target sample size: 30
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT03941444
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
Australia United Kingdom
Contacts
Name:     Walter Kaufmann, MD
Address: 
Telephone: 844-689-3939
Email: rett@anavex.com
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Aged = 18 years, inclusive.

- Diagnosis of classic RTT, according to 2010 criteria (Neul et al., 2010), and a MECP2
mutation.

- Current pharmacological treatment regimen, including supplements, has been stable for
at least 4 weeks.

- If on antiepileptic drugs (AEDs), 1-4 AEDs allowed. Treatment must be stable (drug,
dose, interval of administration) for 30 days prior to enrollment.

- If the subject is already receiving stable non-pharmacologic educational, behavioral,
and/or dietary interventions, participation in these programs must have been
continuous during the 90 days prior to the screening visit and subjects or their
parent/caregiver/legally authorized representative (LAR) will not electively initiate
new or modify ongoing interventions for the duration of the study. 'Study duration' is
defined as lasting from the screening visit until the treatment is terminated. For
participants in the 16-21 years range, typical school vacations are not considered
modifications of stable programming.

- Ability to keep accurate seizure diaries or have caregiver who can keep accurate
seizure diaries.

- Confirmation from the participant that, if of childbearing potential is not pregnant
through urine pregnancy testing. Female patients of childbearing potential and at risk
for pregnancy must agree to abstinence.

- Prior to the conduct of study-specific procedures, the subject's parent/caregiver/LAR
must provide written informed consent. If applicable, the research team

Exclusion Criteria:

- Patients who have a progressive medical or neurological condition that in the opinion
of the Investigator would interfere with the conduct of the study.

- Current clinically significant systemic illness that is likely to result in
deterioration of the patient's condition or affect the patient's safety during the
study.

- History of clinically evident stroke or clinically significant carotid or
vertebrobasilar stenosis or plaque or other history of neurologic (e.g., head trauma
with loss of consciousness) or psychiatric condition that the Investigator deems may
interfere with interpretability of data.

- Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or
alkaline phosphatase above 3x upper limit of normal (ULN) as determined during
screening.

- Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within
the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for
asthma are permitted) or chemotherapeutic agents for malignancy within the last 3
years.

- Other clinically significant abnormality on physical, neurological, laboratory, or
electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise
the study or be detrimental to the participant.

- Any known hypersensitivity to any of the excipients contained in the study drug or
placebo formulation.

- Other co-morbid or chronic illness beyond that known to be associated with RTT.

- Subjects who plan to initiate or change pharmacologic or nonpharmacologic intervention
during the course of the study.

- Subjects taking another investigational drug currently or within the last 30 days.

- Any other criteria (such as a clinically significant screening blood test result),
which in the opinion of the Investigator could interfere with the study conduct or
outcome.

- Subjects on potent CYP3A4 and CYP2C19 inhibitors and inducers.

- Patients with hepatic and renal impairment.



Age minimum: 18 Years
Age maximum: 45 Years
Gender: Female
Health Condition(s) or Problem(s) studied
Rett Syndrome
Intervention(s)
Drug: ANAVEX2-73
Drug: Placebos
Primary Outcome(s)
Area Under the Curve [AUC] of ANAVEX2-73 [Time Frame: 7 weeks]
Incidence of Adverse Events [Time Frame: 7 weeks]
Lipid panel [Time Frame: 7 weeks]
Maximum Plasma Concentration [Cmax] of ANAVEX2-73 [Time Frame: 7 weeks]
Secondary Outcome(s)
CGI-I [Time Frame: 7 weeks]
RSBQ [Time Frame: 7 weeks]
Secondary ID(s)
ANAVEX2-73-RS-002
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history